Recent considerations of actual therapy resistance include newly acquired mechanisms within the AR-axis under the individual treatment and do not necessarily require ultimate castration resistance as in AR-negative cell models of prostate cancer (Feldman and Feldman 2001). This evidence concerns the gene AR and prostate carcinoma.